Current treatment of lupus nephritis

被引：67
作者：
Houssiau, F. A. [1 ]
Ginzler, E. M. [2 ]
机构：
[1] Univ Catholique Louvain, Clin Univ St Luc, Dept Rheumatol, B-1200 Brussels, Belgium
[2] SUNY Hlth Sci Ctr, Div Rheumatol, Brooklyn, NY 11203 USA
来源：
LUPUS | 2008年 / 17卷 / 05期
关键词：
D O I：
10.1177/0961203308090029
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This review on the management of lupus nephritis is based on the results of randomized clinical trials, and discusses the principles of treatment and the current options for induction and maintenance therapy. The respective place of mycophenolate mofetil and intravenous cyclophosphamide are balanced, taking into account efficacy, safety and patients' perspective. The authors anticipate that, in a few years, when long-term data on lupus nephritis patients induced with mycophenolate mofetil becomes available, it is probably that intravenous cyclophosphamide, which has been for so long the 'standard of care', will be prescribed only in specialized conditions such as documented necrotizing vasculitis.
引用
收藏
页码：426 / 430
页数：5
相关论文
共 27 条
[1]   THERAPY OF LUPUS NEPHRITIS - CONTROLLED TRIAL OF PREDNISONE AND CYTOTOXIC DRUGS [J].
AUSTIN, HA ;
KLIPPEL, JH ;
BALOW, JE ;
LERICHE, NGH ;
STEINBERG, AD ;
PLOTZ, PH ;
DECKER, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (10) :614-619
[2]   Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy [J].
Blumenfeld, Z ;
Shapiro, D ;
Shteinberg, M ;
Avivi, I ;
Nahir, M .
LUPUS, 2000, 9 (06) :401-405
[3]   CONTROLLED TRIAL OF PULSE METHYLPREDNISOLONE VERSUS 2 REGIMENS OF PULSE CYCLOPHOSPHAMIDE IN SEVERE LUPUS NEPHRITIS [J].
BOUMPAS, DT ;
AUSTIN, HA ;
VAUGHN, EM ;
KLIPPEL, JH ;
STEINBERG, AD ;
YARBORO, CH ;
BALOW, JE .
LANCET, 1992, 340 (8822) :741-745
[4]  
Cameron JS, 1999, J AM SOC NEPHROL, V10, P413
[5]   Morbidity and mortality in systemic lupus erythematosus during a 10-year period -: A comparison of early and late manifestations in a cohort of 1,000 patients [J].
Cervera, R ;
Khamashta, MA ;
Font, J ;
Sebastiani, GD ;
Gil, A ;
Lavilla, P ;
Mejía, JC ;
Aydintug, AC ;
Chwalinska-Sadowska, H ;
de Ramón, E ;
Fernández-Nebro, A ;
Galeazzi, M ;
Valen, M ;
Mathieu, A ;
Houssiau, FD ;
Caro, N ;
Alba, P ;
Ramos-Casals, M ;
Ingelmo, M ;
Hughes, GRV .
MEDICINE, 2003, 82 (05) :299-308
[6]   Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis [J].
Chan, TM ;
Li, FK ;
Tang, CSO ;
Wong, RWS ;
Fang, GX ;
Ji, YL ;
Lau, CS ;
Wong, AKM ;
Tong, MKL ;
Chan, KW ;
Lai, KN .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (16) :1156-1162
[7]   Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis [J].
Chan, TM ;
Tse, KC ;
Tang, CSO ;
Mok, MY ;
Li, FK .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (04) :1076-1084
[8]   Sequential therapies for proliferative lupus nephritis [J].
Contreras, G ;
Pardo, V ;
Leclercq, B ;
Lenz, O ;
Tozman, E ;
O'Nan, P ;
Roth, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (10) :971-980
[9]   Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans [J].
Dooley, MA ;
Hogan, S ;
Jennette, C ;
Falk, R .
KIDNEY INTERNATIONAL, 1997, 51 (04) :1188-1195
[10]   Relapses of lupus nephritis:: incidence, risk factors, serology and impact on outcome [J].
El Hachmi, M ;
Jadoul, M ;
Lefèbvre, C ;
Depresseux, G ;
Houssiau, FA .
LUPUS, 2003, 12 (09) :692-696
123